MOTS-c
MOTS-c during exercise and in experiments
An endogenous signal has a starting condition of its own. Changing that signal experimentally raises a further set of questions.
Exercise and administered MOTS-c
The exercise study contains two ideas that are easy to run together: exercise induces the body’s own MOTS-c in skeletal muscle and circulation, and administered MOTS-c enhanced physical performance in mice. I give the first finding room to breathe before moving to the second. A physiological response to exertion is interesting in its own right.
In the animal experiments, improved running capacity, grip strength and gait extended to aged mice. That supports further investigation of administered MOTS-c. It also raises the question behind this site: how much of a change lasts after the intervention ends? The results collected here provide no human efficacy trial, let alone a human withdrawal result. My curiosity about an exercise-related signal survives without treating an animal performance result as an established human benefit.
What it is
MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene, MT-RNR1. The review of its stress, metabolism and aging biology brings together that unusual genetic origin and its effects in cells and animals. Mitochondria have their own DNA; this small signal comes from there.
The body’s production of MOTS-c makes the baseline especially important. An endogenous peptide level, the response to exercise and the effect of administering additional peptide each describe something different. Being a copy of a naturally occurring signal supplies a biological rationale for experiments. Human benefit and safety still need to be measured.
Access boundary
Keep evidence and access in separate columns
MOTS-c's investigational evidence and its prescription route answer different questions: Promise Peptides (mypromise.com) currently prescribes the compounded medication as Rx-only care. Prescribing rests with a licensed U.S. clinician after a case-by-case assessment, and refusals are part of that process. The practice serves U.S. patients exclusively; state requirements and the particular treatment restrict its offerings. The MOTS-c medication made by compounding has no FDA approval.
Cellular responses under stress
In the mechanistic literature summarized by Wan and colleagues, MOTS-c inhibits the folate cycle, raising AICAR and activating AMPK, a protein involved in sensing cellular energy availability. The reported improvements in glucose handling and insulin sensitivity come from experimental work, predominantly in cells and rodents.
The nuclear-translocation study used human and mouse cells. Under metabolic stress, MOTS-c moved to the nucleus and affected stress-responsive gene expression through AMPK-dependent signaling and interaction with NRF2. The CK2 study added a direct binding target using cell-free assays and mouse experiments; it reported CK2 activation in muscle and suppression in fat.
Context is the arresting feature for me. A signal associated with exertion also responds to cellular stress, and its reported action varies by tissue. That makes the proposition of simply adding more less straightforward than the word natural suggests.
Human observations
The prospective hemodialysis cohort followed 94 people and associated circulating MOTS-c with a composite of all-cause mortality and non-fatal cardiovascular events. Adding the measured peptide level improved the risk model’s discrimination. Nobody was assigned MOTS-c to test a treatment benefit in that study.
I’d be more convinced by an intervention trial that measures the outcomes people seek, followed by observation after treatment ends. The present human biomarker findings cannot provide that sequence. The review also describes genotype and ancestry interactions, and some mechanistic findings await replication. The evidence gives ample reason to investigate, alongside ample room for a result to change.
There is no validated human pharmacokinetic profile or established human efficacy and safety profile in this material. Laboratory-use supplies vary in identity, purity and sterility. MOTS-c has no FDA approval and is prohibited in competitive sport under the anti-doping status recorded here. The FAQ addresses its regulatory listing and the difference between a compounded prescription route and evidence of clinical benefit.